Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model

Abstract

Recombinant human interleukin-2 (rhIL-2) therapy is approved for treating patients with advanced melanoma yet significant responses are observed in only 10–15% of patients. Interleukin-2 induces Foxp3 expression in activated human CD8 T cells in vitro and expands circulating CD8 Foxp3+ T cells in melanoma patients. Employing IL-2 responsive (B16-F1, B16-BL6… (More)
DOI: 10.1007/s00262-011-1035-1

Topics

6 Figures and Tables

Cite this paper

@article{Foureau2011SkinTR, title={Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model}, author={David M. Foureau and Iain H Mckillop and Chase P. Jones and Asim Amin and Richard L. White and Jonathan C. Salo}, journal={Cancer Immunology, Immunotherapy}, year={2011}, volume={60}, pages={1347-1356} }